Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by ARK Invest. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ARK Invest or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

AI Meets Biotech: The Future Of Protein Therapeutics With Mike Nally And Jason Silvers

1:06:38
 
Share
 

Manage episode 485611160 series 1532639
Content provided by ARK Invest. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ARK Invest or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this episode of FYI – For Your Innovation, Brett Winton and ARK analyst Nemo Despot sit down with Generate Biomedicines CEO Mike Nally and CFO Jason Silvers to explore how generative AI is transforming the discovery and development of protein-based therapeutics. Founded in 2018 by Flagship Pioneering, Generate Biomedicines is building a “self-driving lab” that combines machine learning, cryo-electron microscopy (cryo-EM), and high-throughput wet lab automation to dramatically accelerate drug development. The conversation dives into how Generate is reimagining protein therapeutics — going beyond trial-and-error methods to a data-first, design-driven model for creating novel medicines. The team discusses the company’s proprietary approach to integrating structural biology with functional data, the economic implications of reducing time-to-market from 13 years to under 9, and how their platform could unlock treatments for diseases that have been historically undruggable. They also touch on strategic partnerships, scalability, and how AI is shifting the biotech business model from artisanal science to an industrialized, data-driven enterprise.

Key Points From This Episode:

  • 00:01:30 Why Generate Biomedicines is rethinking protein drug discovery from first principles
  • 00:04:40 How their structure-first approach differs from peers like AbSci and Recursion
  • 00:07:04 Using cryo-EM to build proprietary protein interaction datasets
  • 00:10:57 Traditional drug discovery is random, expensive, and inefficient — here’s how Generate is changing that
  • 00:16:58 From concept to clinic in 18–24 months: Accelerating timelines through AI
  • 00:20:47 Going beyond efficiency: Unlocking access to undruggable biology
  • 00:24:48 Turning cryo-EM into a high-throughput data engine for model training
  • 00:31:20 The long-term vision: Patient-specific protein therapeutics
  • 00:40:00 Why scalability gives Generate an edge over traditional biotech
  • 00:47:52 The future of biotech as a research & development (R&D) sharing economy
  • 00:54:19 Adapting fast: Keeping pace with generative AI advances across the stack
  • 01:00:16 The KPI (key performance indicator) for platform success: Rate of improvement
  continue reading

374 episodes

Artwork
iconShare
 
Manage episode 485611160 series 1532639
Content provided by ARK Invest. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ARK Invest or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this episode of FYI – For Your Innovation, Brett Winton and ARK analyst Nemo Despot sit down with Generate Biomedicines CEO Mike Nally and CFO Jason Silvers to explore how generative AI is transforming the discovery and development of protein-based therapeutics. Founded in 2018 by Flagship Pioneering, Generate Biomedicines is building a “self-driving lab” that combines machine learning, cryo-electron microscopy (cryo-EM), and high-throughput wet lab automation to dramatically accelerate drug development. The conversation dives into how Generate is reimagining protein therapeutics — going beyond trial-and-error methods to a data-first, design-driven model for creating novel medicines. The team discusses the company’s proprietary approach to integrating structural biology with functional data, the economic implications of reducing time-to-market from 13 years to under 9, and how their platform could unlock treatments for diseases that have been historically undruggable. They also touch on strategic partnerships, scalability, and how AI is shifting the biotech business model from artisanal science to an industrialized, data-driven enterprise.

Key Points From This Episode:

  • 00:01:30 Why Generate Biomedicines is rethinking protein drug discovery from first principles
  • 00:04:40 How their structure-first approach differs from peers like AbSci and Recursion
  • 00:07:04 Using cryo-EM to build proprietary protein interaction datasets
  • 00:10:57 Traditional drug discovery is random, expensive, and inefficient — here’s how Generate is changing that
  • 00:16:58 From concept to clinic in 18–24 months: Accelerating timelines through AI
  • 00:20:47 Going beyond efficiency: Unlocking access to undruggable biology
  • 00:24:48 Turning cryo-EM into a high-throughput data engine for model training
  • 00:31:20 The long-term vision: Patient-specific protein therapeutics
  • 00:40:00 Why scalability gives Generate an edge over traditional biotech
  • 00:47:52 The future of biotech as a research & development (R&D) sharing economy
  • 00:54:19 Adapting fast: Keeping pace with generative AI advances across the stack
  • 01:00:16 The KPI (key performance indicator) for platform success: Rate of improvement
  continue reading

374 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play